This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal population in the western region of Sweden. The aim is to improve diagnosis of ovarian cancer. If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.
The investigators are currently using CA125 and RMI in diagnosing patients with a pelvic cyst/tumor and referring them to tertiary centers for surgery in the western region of Sweden. The diagnostic accuracy is unsatisfying why the investigators are evaluating HE4 and ROMA as a complement, in combination or separately to improve diagnostic accuracy. The trial is based on a normal population cohort of patients included at all the hospitals in the region. The patients were included before surgery and the biomarkers analysed on serum samples withdrawn preoperatively. If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.
Study Type
OBSERVATIONAL
Enrollment
684
Improving diagnosis
Gothenburg University, Sahlgrenska University Hospital
Gothenburg, Gothenburg, Sweden
Can the investigators improve diagnostic accuracy in women diagnosed with a cyst/tumor in the pelvis
Finding the true cases and avoiding unnecessary surgery, a descriptive analysis of a normalpopulation
Time frame: 12 months
Improve triage of patients to tertiary centers for surgery
Referring the correct cases from a normal population.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.